KRAS and non-small cell lung carcinoma: In NSCLC, codon 12 is the most common site for KRAS point mutations, and glycine-to-cysteine (mKRAS G12C) (40–50% of all KRAS mutations) is present in 10–13% of LUAD patients [13,14].